# BRIEFING — 2026-09-22T00:47:30+05:30

## Mission
Extract verified, rigorous medical and clinical facts from Opus1.md into clinical_ledger.md and produce handoff.md across the 4 clinical domains.

## 🔒 My Identity
- Archetype: explorer
- Roles: Clinical Colonoscopy, Polyp Classification & Commercial CADe/CADx Specialist
- Working directory: C:\Users\imgk3\teamwork_projects\colonoscopy_ai_guide\.agents\explorer_m1_1
- Original parent: 6cbe56b6-48be-422f-b717-c93c477a23c6
- Milestone: M1 — Content Extraction & Medical/Clinical Ledger

## 🔒 Key Constraints
- Read-only investigation — do NOT implement site code (read Opus1.md and produce analysis in .agents/explorer_m1_1/)
- Zero hallucinations: verify every claim, number, and study author directly against Opus1.md
- Include exact quotes, line numbers/sections from Opus1.md, and full citations
- Output files: clinical_ledger.md, handoff.md, progress.md in working directory
- Network: CODE_ONLY mode

## Current Parent
- Conversation ID: 6cbe56b6-48be-422f-b717-c93c477a23c6
- Updated: not yet

## Investigation State
- **Explored paths**:
  - `C:\Users\imgk3\teamwork_projects\pdf_to_markdown\Opus1.md` (lines 1 to 19,236; specifically lines 8–47, 61–78, 152–165, 334–358, 396–432, 465–506, 538–555, 3725–3736, 9609–9620, 13702–13706, 14234–14262)
  - `C:\Users\imgk3\teamwork_projects\pdf_to_markdown\extracted_source.json` (all 425 pages)
  - `C:\Users\imgk3\Downloads\ChakraModel Research Status & Roadmap.pdf` (pages 1 to 17)
- **Key findings**:
  - Domain 1: All 8 anatomical segments, BBPS (0–9 scale, $\ge$6 adequate), CIR ($\ge$95%), withdrawal time ($\ge$6 min minimum, 8–9 min optimal), Corley et al. landmark study (1% ADR $\rightarrow$ 3% CRC drop, 5% fatal CRC drop), ADR vs PDR ($\approx$ 0.65–0.70 factor), AMR (20–26% baseline, up to 35% flat/diminutive).
  - Domain 2: Paris classification (0-I, 0-Ip, 0-Is, 0-IIa, 0-IIb, 0-IIc, 0-III, LST), size tiers ($\le$5mm diminutive, 6–9mm small, $\ge$10mm large), dual histological pathways (conventional adenoma-carcinoma APC/KRAS/TP53 vs serrated pathway BRAF/CIMP/MSI-H), and optical systems (Kudo I–V, NICE 1–3, JNET 1–3).
  - Domain 3: Landmark RCTs (Wang Gut 2019, Lancet Oncol 2019, GIE 2020; Repici Gastro 2020; Mori, Wallace, Hassan), 2024 meta-analysis (RR 1.20 ADR, RR 0.45 AMR), 2025 GI Genius meta-analysis (ADR RR 1.12, SSL RR 1.27, advanced adenoma RR 1.01), Maida 2026 network meta-analysis (41 RCTs, 31,789 pts), AGA model (8% ADR gain, 2% advanced gain, 11 fewer CRC, 2 fewer deaths, 6–35 extra surveillance colonoscopies per 10k, non-neoplastic resections 28.8% $\rightarrow$ 34.0%), Budzyń 2025 ACCEPT trial deskilling (-6.0% ADR drop), ASGE PVI criteria ($\ge$90% NPV), 2025 guideline schism (AGA, ESGE, BMJ, WEO).
  - Domain 4: Commercial systems profile across GI Genius, CAD EYE, ENDO-AID, WISE VISION, Discovery, MAGENTIQ-COLO (<40ms latency budget, inline appliance).
- **Unexplored areas**: None for M1-1 scope. Fully extracted and compiled.

## Key Decisions Made
- Compiled exhaustive, 764-line clinical ledger at `C:\Users\imgk3\teamwork_projects\colonoscopy_ai_guide\.agents\explorer_m1_1\clinical_ledger.md`.
- Verified all quotes and quantitative invariants line-by-line against `Opus1.md`.

## Artifact Index
- `C:\Users\imgk3\teamwork_projects\colonoscopy_ai_guide\.agents\explorer_m1_1\ORIGINAL_REQUEST.md` — Original mission request
- `C:\Users\imgk3\teamwork_projects\colonoscopy_ai_guide\.agents\explorer_m1_1\progress.md` — Liveness & heartbeat
- `C:\Users\imgk3\teamwork_projects\colonoscopy_ai_guide\.agents\explorer_m1_1\clinical_ledger.md` — Authoritative Clinical Evidence Ledger (764 lines, 79.8 KB)
- `C:\Users\imgk3\teamwork_projects\colonoscopy_ai_guide\.agents\explorer_m1_1\handoff.md` — 5-component handoff report
